A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy
Latest Information Update: 07 Jan 2025
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HANNA
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results (data cutoff date: 16 Jan 2023) of an updated analysis at a median follow-up was 44.4 months in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck presented at the 48th European Society for Medical Oncology Congress
- 13 Sep 2022 Interim Results (January 2022), presented at the 47th European Society for Medical Oncology Congress
- 01 Nov 2021 Results (n=782) of a pooled analysis assessing real-world effectiveness of nivolumab in patients with relapsed metastatic SCCHN from a United States Flatiron Health database and German HANNA study published in the Head and Neck